


## 2016-2018 Interim Evaluation

The evaluation for the current 2016-2018 waiver period will build on information about program enrollment, utilization, and costs as reported in earlier evaluations.


This waiver renewal application presents some preliminary descriptive data related to program enrollment, member characteristics, and program utilization and costs. Data for these measures have been drawn from SeniorCare program enrollment and claims data. In addition to the data reported here, other components of the evaluation are in progress and will be reported in the final evaluation report next year.

### Tables/Charts

The tables and charts below provide descriptive data on the SeniorCare waiver population, which is denoted as “SC1.”



### SeniorCare Enrollment by Age




### SeniorCare Length of Enrollment

Years of Enrollment	Members	Percent of Total	Members (Cumulative)	Percent of Total (Cumulative)
0 - 1	5,958	14%	5,958	14%
1 - 2	5,313	12%	11,271	26%
2 - 3	4,269	10%	15,540	36%
3 - 4	3,505	8%	19,045	44%
4 - 5	3,059	7%	22,104	51%
5 - 6	2,257	5%	24,361	56%
6 - 7	1,989	5%	26,350	61%
7 - 8	2,348	5%	28,698	66%

8 - 9	2,118	5%	30,816	71%
9 - 10	1,285	3%	32,101	74%
10 - 11	1,054	2%	33,155	77%
11 - 12	2,172	5%	35,327	82%
12 - 13	1,618	4%	36,945	85%
13 - 14	1,230	3%	38,175	88%
14 - 15	1,639	4%	39,814	92%
15 - 16	3,443	8%	43,257	100%
<b>Total</b>	<b>43,257</b>	100%	43,257	100%

### Enrollment by Prescription Drug Coverage



### SeniorCare Claims/Payments

Drug Type	Claims (Unique ICN)	Percent of Total	Total Paid Amount	Percent of Total	Average Paid Amount
BRAND	223,093	13.8%	\$ 81,886,430.90	84.0%	\$ 367.05
GENERIC	1,289,497	80.0%	\$ 15,418,588.07	15.8%	\$ 11.96
SPECIALTY		0.0%		0.0%	
OTHER	99,027	6.1%	\$ 176,872.87	0.2%	\$ 1.79
<b>Total</b>	<b>1,611,617</b>	<b>100%</b>	<b>\$ 97,481,891.84</b>	<b>100%</b>	<b>\$ 60.49</b>

### SeniorCare Top 25 Drugs Paid in CY2017

Drug Name	Claims	Percent of Total	Total Paid	Percent of Total
INSULINS	39,607	6%	\$ 2,883,323.72	18%
ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS	1,129	0%	\$ 9,327,080.01	13%
BETA-ADRENERGIC AND GLUCOCORTICOID COMBO, INHALED	25,916	4%	\$ 6,393,010.03	9%
ANTINEOPLASTIC IMMUNOMODULATOR AGENTS	454	0%	\$ 4,995,586.95	7%
DIRECT FACTOR XA INHIBITORS	17,482	3%	\$ 4,746,810.17	7%
ANTI-INFLAMMATORY TUMOR NECROSIS FACTOR INHIBITOR	1,388	0%	\$ 4,423,489.69	6%
ANTICHOLINERGICS, ORALLY INHALED LONG ACTING	14,809	2%	\$ 3,866,694.70	5%
ANTINEOPLASTIC - ANTIANDROGENIC AGENTS	836	0%	\$ 2,716,139.49	4%
ANTHYPERGLYCEMIC, DPP-4 INHIBITORS	8,605	1%	\$ 2,372,714.86	3%
ANTICONVULSANTS	50,478	8%	\$ 2,281,592.12	3%
MIOTICS AND OTHER INTRAOCULAR PRESSURE REDUCERS	41,324	6%	\$ 2,269,450.31	3%
URINARY TRACT ANTISPASMODIC, M(3) SELECTIVE ANTAG.	6,430	1%	\$ 1,611,912.75	2%
ANTHYPERLIPIDEMIC - HMG COA REDUCTASE INHIBITORS	98,361	15%	\$ 1,271,605.29	2%
BETA-ADRENERGIC AND ANTICHOLINERGIC COMBO, INHALED	6,426	1%	\$ 1,268,303.85	2%
LIPOTROPICS	12,084	2%	\$ 1,245,496.33	2%
PROTON-PUMP INHIBITORS	92,069	14%	\$ 1,090,677.44	2%
BETA-ADRENERGIC BLOCKING AGENTS	77,828	12%	\$ 1,031,517.14	1%
ANTIARRHYTHMICS	9,981	2%	\$ 1,003,867.84	1%
THYROID HORMONES	48,354	8%	\$ 910,458.39	1%
ANTINEOPLASTIC - JANUS KINASE (JAK) INHIBITORS	85	0%	\$ 865,976.54	1%
ANALGESICS, NARCOTICS	30,244	5%	\$ 847,564.28	1%
ANTHYPERGLY,INCRETIN MIMETIC(GLP-1 RECEP.AGONIST)	1,855	0%	\$ 797,598.58	1%
GLUCOCORTICIDS, ORALLY INHALED	4,958	1%	\$ 782,681.44	1%
POTASSIUM REPLACEMENT	43,476	7%	\$ 747,876.88	1%
DRUG TX-CHRONIC INFLAM. COLON DX,5-AMINOSALICYLAT	2,311	0%	\$ 725,938.39	1%
<b>TOTALS</b>	<b>636,490</b>	<b>100%</b>	<b>\$ 70,477,367.19</b>	<b>100%</b>